Table 3 from First-in-Human Dose-Escalation Study of Fianlimab, an Antilymphocyte Activation Gene-3 Antibody, with Cemiplimab in Patients with Advanced Malignancies
收藏数据链接：
官方服务：
资源简介：
Investigator-assessed tumor response rate by Response Evaluation Criteria in Solid Tumors version 1.1.
创建时间：
2024-12-16
